Sotabase

Career

· SoC Power Engineer, Apple2024–2024
· Devices Lead, Neurotech@Berkeley2023–2024
· Imaging Intern, STMicroelectronics2023–2023
· Senior Mentor, EECS16AB, Computer Science Mentors2022–2024
· Academic Intern, CS61A, University of California, Berkeley2022–2022
· Academic Student Employee, Course Reader, EECS16A, University of California, Berkeley2022–2022
· B.S. Computer Science, University of California, Berkeley2021–2025
· B.S. Electrical Engineering and Computer Sciences, University of California, Berkeley2021–2025
· PhD Student, Electrical Engineering and Computer Sciences, University of California, Berkeley2021–
· Undergraduate Student, University of California, Berkeley2021–2025
· Researcher, Berkeley Wireless Research Center (BWRC)
· Graduate Student, Muller Lab @ UC Berkeley

Publications (123)

Resistance to Acalabrutinib in CLL Is Mediated Primarily By BTK Mutations
Blood · 2019
86
cited
Cardiovascular Toxicities of BTK Inhibitors in Chronic Lymphocytic Leukemia
JACC CardioOncology · 2023
81
cited
Incidence of opportunistic infections during ibrutinib treatment for B-cell malignancies
Leukemia · 2019
74
cited
Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naïve and Relapsed or Refractory Chronic Lymphocytic Leukemia.
Journal of Clinical Oncology · 2020
74
cited
Final Results of Phase 1, Dose Escalation Study Evaluating ARQ 531 in Patients with Relapsed or Refractory B-Cell Lymphoid Malignancies
Blood · 2019
69
cited
Clinical activity of axicabtagene ciloleucel in adult patients with Richter syndrome.
Blood Advances · 2020
66
cited
Acalabrutinib Plus Obinutuzumab in Treatment-Naive and Relapsed/Refractory Chronic Lymphocytic Leukemia.
Cancer Discovery · 2020
63
cited
Ventricular Arrhythmias and Sudden Death Events following Acalabrutinib initiation.
Blood · 2022
59
cited
Distinct cellular and therapeutic effects of obatoclax in rituximab‐sensitive and ‐resistant lymphomas
British Journal of Haematology · 2011
52
cited
Second Cancer Incidence in CLL Patients Receiving BTK Inhibitors
Leukemia · 2019
52
cited
The impact of increasing karyotypic complexity and evolution on survival in CLL patients treated with ibrutinib.
Blood · 2021
42
cited
Interdigitating dendritic cell sarcoma.
The Journal of the National Comprehensive Cancer Network · 2015
41
cited
Hairy cell leukemia and COVID-19 adaptation of treatment guidelines
Leukemia · 2021
33
cited
Hairy Cell Leukemia, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology.
The Journal of the National Comprehensive Cancer Network · 2017
33
cited
Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: An International, Multicenter, Retrospective Study
Journal of Clinical Oncology · 2024
31
cited
First in Human Study of the Reversible BTK Inhibitor Nemtabrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia and B-Cell Non-Hodgkin Lymphoma.
Cancer Discovery · 2023
31
cited
Hypertension and incident cardiovascular events after next-generation BTKi therapy initiation
Journal of Hematology & Oncology · 2022
31
cited
Cardiovascular Magnetic Resonance Imaging in Patients With Ibrutinib-Associated Cardiotoxicity.
JAMA Oncology · 2023
24
cited
Selinexor combined with ibrutinib demonstrates tolerability and safety in advanced B-cell malignancies: A phase I study.
Clinical Cancer Research · 2022
23
cited
Galiximab: a review
Expert Opinion on Biological Therapy · 2010
22
cited
Sotabase
Savit Bhat | Researcher Profile | Sotabase | Sotabase